CellaVision AB

Chart & Performance

D1W1MN

P/E

30.88

P/S

6.01

EPS

5.90

Div Yield, %

1.23%

Shrs. gr., 5y

—

Rev. gr., 5y

9.39%

Revenues

723m

+6.78%

Net income

141m

+7.99%

CFO

198m

+1.02%

Dividend

May 07, 20252.5 SEK/sh

Profile

CellaVision AB (publ) develops and sells digital solutions for blood and body fluids analysis in health care services sector in Sweden, Europe, the Middle East, Africa, the Americas, and the Asia Pacific. The company provides CellaVision DM1200 and CellaVision DM9600, which automatically capture digital images of cells from blood smears and body fluid preparations; and CellaVision DC-1, an analyzer. It also offers CellaVision Peripheral Blood Application that enables laboratories to automate, standardize, and simplify morphological examination of peripheral blood smears; CellaVision Advanced RBC Application, which enables to perform comprehensive examination of red blood cell morphology; CellaVision Body Fluid Application that enables laboratories to automate, standardize, and simplify morphological examination of body fluid preparations; and CellaVision Remote Review Software, which removes restrictive geographical constraints from the smear review process. In addition, the company provides CellaVision Server Software that creates a single streamlined workflow within one or multiple testing sites; CellaVision Dashboard, a tool designed to give an at-a-glance view of CellaVision analyzer and reviewer metrics; CellaVision Proficiency Software, a cloud-based software designed to help laboratory managers assess, monitor, and promote staff competency in the area of cell morphology; CellaVision CellAtlas, which combines a series of mini lectures with an extensive cell image library; and CellaVision VET that offers digital solutions for medical microscopy in the field of hematology. It sells its products to hospital and commercial laboratories. CellaVision AB (publ) was incorporated in 1994 and is headquartered in Lund, Sweden.

URL

https://www.cellavision.com/

IPO date

May 28, 2007

Employees

235

Domiciled in

Incorporated in

Valuation

Order:

Title SEK in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title SEK in thousands, except ratios and share amounts	2024‑12	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12	2015‑12
Income
Revenues	723,217 6.78%	677,292 5.94%	639,340 13.05%
Cost of revenue	545,539	510,240	481,074
Unusual Expense (Income)
NOPBT	177,678	167,052	158,266
NOPBT Margin	24.57%	24.66%	24.75%
Operating Taxes	36,138	33,913	30,094
Tax Rate	20.34%	20.30%	19.01%
NOPAT	141,540	133,139	128,172
Net income	140,722 7.99%	130,309 10.12%	118,335 -5.59%
Dividends	(53,666)	(53,666)	(47,703)
Dividend yield	1.03%	1.06%	0.87%
Proceeds from repurchase of equity
BB yield
Debt
Debt current	14,171	36,039	42,131
Long-term debt	12,678	59,611	98,249
Deferred revenue
Other long-term liabilities	6,254	4,945	3,739
Net debt	(122,581)	(30,391)	26,987
Cash flow
Cash from operating activities	198,438	196,436	137,285
CAPEX	(77,749)	(31,769)	(69,434)
Cash from investing activities	(76,006)	(85,532)	(70,014)
Cash from financing activities	(95,089)	(97,036)	(90,410)
FCF	150,139	134,318	61,076
Balance
Cash	149,430	121,645	108,053
Long term investments		4,396	5,340
Excess cash	113,269	92,176	81,426
Stockholders' equity		705,589	630,828
Invested Capital	848,829	693,861	666,378
ROIC	18.35%	19.58%	20.95%
ROCE	19.35%	19.76%	19.77%
EV
Common stock shares outstanding	23,852	23,852	23,852
Price	217.50 2.59%	212.00 -7.42%	229.00 -29.58%
Market cap	5,187,711 2.59%	5,056,624 -7.42%	5,462,108 -29.58%
EV	5,065,130	5,026,233	5,489,095
EBITDA	177,678	206,815	198,363
EV/EBITDA	28.51	24.30	27.67
Interest	8,159	3,260	2,340
Interest/NOPBT	4.59%	1.95%	1.48%